Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

Abstract: The present disclosure relates to methods for determining the metabolic responder status of a subject having glioblastoma (GBM) and adjusting the course of treatment accordingly. The disclosure further relates to methods of treating GBM and other EGFR-mediated cancers. The disclosure further relates to methods of identifying effective treatments for subjects having GBM.

Abstract: The present disclosure relates to compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR-mediated cancers, such as those that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

Abstract: The present disclosure relates to a method of treating a glioblastoma by conjointly administering to a subject a BCL-xL inhibitor and a second therapy such as an alkylating agent, irradiation, or an MCL-1 inhibitor.

Abstract: Disclosed herein are Zika virus constructs and methods of using Zika virus constructs and Zika viruses to treat subjects in need thereof.

Abstract: The present disclosure relates to compounds, compositions and methods for treating cancer, including compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating cancer in the brain, including glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating cancers such as glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

Abstract: The present disclosure relates to compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR-mediated cancers, such as those that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

Abstract: Described herein, inter alia, are anti-cancer agents, anti-cancer pharmaceutical compositions, combinations of the agents and/or pharmaceutical compositions, and methods of using the same.

Abstract: Provided herein are compounds that bind to dCK and methods for treating cancer.

Abstract: A method of establishing personalized limits on a search responsive to a key word query in an enterprise search system is described that includes receiving an object types access history for a particular user. Applying this method, the object types access history includes records of object types selected from search results returning multiple object types and records of object types selected via interfaces other than search results. The method continues with determining and storing in computer readable memory a personalized scope of object types. The personalized scope of object types sets a limit on object types initially returned by an enterprise search system for the particular user in response to key word queries by the particular user that do not specify object types to search.

Abstract: Provided herein are compounds that bind to dCK and methods for treating cancer.

Abstract: The invention provides compounds that bind to deoxycytidine kinase (dCK) and compositions including pharmaceutically acceptable compositions containing the compounds. The compounds are useful in treating diseases and disorders where dCK activity is implicated such as cancer and immune disorders. The compounds also find use in clinical methodologies including positron emission tomography (PET) imaging.

Abstract: A method of establishing personalized limits on a search responsive to a key word query in an enterprise search system is described that includes receiving an object types access history for a particular user. Applying this method, the object types access history includes records of object types selected from search results returning multiple object types and records of object types selected via interfaces other than search results. The method continues with determining and storing in computer readable memory a personalized scope of object types. The personalized scope of object types sets a limit on object types initially returned by an enterprise search system for the particular user in response to key word queries by the particular user that do not specify object types to search.

Abstract: Provided herein are compounds that bind to dCK and methods for treating cancer.

Abstract: Provided herein are compounds that bind to dCK and methods for treating cancer.

Abstract: A method of establishing personalized limits on a search responsive to a key word query in an enterprise search system is described that includes receiving an object types access history for a particular user. Applying this method, the object types access history includes records of object types selected from search results returning multiple object types and records of object types selected via interfaces other than search results. The method continues with determining and storing in computer readable memory a personalized scope of object types. The personalized scope of object types sets a limit on object types initially returned by an enterprise search system for the particular user in response to key word queries by the particular user that do not specify object types to search.

Abstract: The present invention provides a system and method to process items for sale or bid, to transmit electronic negotiations between prospective buyer and seller, and to verify the condition of the item before delivery to the buyer. The invention facilitates autonomous and remote negotiation between sellers and prospective buyers while protecting buyers from fraud and item misrepresentation. With the present invention, items can be sold individually and are not treated as standardized items that are interchangeable with similar commodity goods. The present invention also provides a waitlisting function. In addition, the functionality of traditional auction systems may be integrated with the novel features of the present invention. Furthermore, the present invention provides a system and method for conducting a reverse auction by allowing prospective buyers to list desired items.